Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19
CONCLUSION: DAP inhibited the proliferation, migration, and invasion and promoted the apoptosis of MM cells. Mechanistically, the RPS19 expression was significantly decreased in DAPtreated cells. This research provides a potential therapeutic drug for MM therapy.PMID:38454765 | DOI:10.2174/0113862073283460240129104114 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - March 8, 2024 Category: Chemistry Authors: Yijun Zhuang Yin Zhang Caiyun Chen Jincheng Chen Qiuxia Xu Peihong Wang Source Type: research
An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation
DiscussionThese case studies and our previous experience suggest that to achieve an effective reduction of anti-rhGAA antibodies in the setting of HSAT, bortezomib should be initiated at the earliest sign of high anti-rhGAA antibodies with a minimum of two consecutive cycles as shown in the case of patient 8. It is important to note that, despite initiation of ERT at age 2.3 weeks, patient 8 quickly developed HSAT. We recommend close monitoring of anti-rhGAA antibodies and early intervention with ITI as soon as significantly elevated anti-rhGAA antibody titers are noted. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 8, 2024 Category: Allergy & Immunology Source Type: research
Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India
ConclusionAt the current WTP threshold of one-time per capita GDP ( ₹ 146,890) of India, VRd alone and VRd plus AHSCT has 38.1% and 6.9% probability to be cost-effective, respectively. Reduction in current reimbursement rates of novel drugs, namely VRd, lenalidomide, and pomalidomide plus dexamethasone under national insurance program and societal cost of transpla nt by 50%, would make VRd plus AHSCT and VTd plus AHSCT cost-effective at an incremental cost of ₹40,671 (US$34) and ₹97,639 (US$1,281) per QALY gained, respectively. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - March 7, 2024 Category: Health Management Source Type: research
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells
Oncotarget. 2024 Mar 5;15:159-174. doi: 10.18632/oncotarget.28558.ABSTRACTGZ17-6.02, a synthetically manufactured compound containing isovanillin, harmine and curcumin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with a recommended phase 2 dose (RP2D) of 375 mg PO BID. GZ17-6.02 was more efficacious as a single agent at killing multiple myeloma cells than had previously been observed in solid tumor cell types. GZ17-6.02 interacted with proteasome inhibitors in a greater than additive fashion to kill myeloma cells and alone it killed inhibitor-resistant cells to a similar extent. The drug co...
Source: Oncotarget - March 5, 2024 Category: Cancer & Oncology Authors: Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells
Oncotarget. 2024 Mar 5;15:159-174. doi: 10.18632/oncotarget.28558.ABSTRACTGZ17-6.02, a synthetically manufactured compound containing isovanillin, harmine and curcumin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with a recommended phase 2 dose (RP2D) of 375 mg PO BID. GZ17-6.02 was more efficacious as a single agent at killing multiple myeloma cells than had previously been observed in solid tumor cell types. GZ17-6.02 interacted with proteasome inhibitors in a greater than additive fashion to kill myeloma cells and alone it killed inhibitor-resistant cells to a similar extent. The drug co...
Source: Oncotarget - March 5, 2024 Category: Cancer & Oncology Authors: Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
Multiple myeloma is an incurable cancer that originates from antibody-producing plasma cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin-like proteins. The high rate of synthesis makes myeloma cells dependent on protein processing mechanisms related to the proteasome. This dependence made proteasome inhibitors such as bortezomib and carfilzomib one of the most important classes of drugs used in multiple myeloma treatment. Inhibition of the proteasome is associated with alteration of a number of important biological processes leading, in consequence, to inhibition of angiogenesis....
Source: Frontiers in Pharmacology - March 4, 2024 Category: Drugs & Pharmacology Source Type: research
Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting
CONCLUSION: Achieving at least a VGPR significantly associated with better outcome in NDMM patients. In a resource constrain country, we recommend incorporating bortezomib in the induction therapy followed with an upfront ASCT.PMID:38415546 | DOI:10.31557/APJCP.2024.25.2.595 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - February 28, 2024 Category: Cancer & Oncology Authors: Chin Sum Cheong Tengku Ahmad Hidayat Tengku K Aziz Nur Adila Anuar Ping Chong Bee Edmund Fui Min Chin Shasha Khairullah Chee Chiat Liong Yazid Zamri Gin Gin Gan Source Type: research
